

Aetna covers breast cancer test from NanoString

NanoString Technologies has received a positive coverage decision from Aetna for Prosigna, a test for evaluating the prognosis and disease recurrence risk in patients with certain types of hormone receptor-positive breast cancer using the PAM50 gene expression signature. The decision adds the in vitro diagnostic test to Aetna's Tumor Markers Clinical Policy Bulletin.

[GenomeWeb Daily News \(free registration\)](#) (5/9)